series-c-plus
Stage
1
Investors
About
INFEX Therapeutics acquires, develops, and licenses innovative anti-infective drugs to treat pandemic and drug-resistant infections, advancing clinical programs including RESP-X (INFEX702) into Phase IIa trials.
Explore INFEX Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.